ライフサイエンスコーパス: synovial sarcoma

1 osarcoma, malignant fibrous histiocytoma, or synovial sarcoma.

2 study of 243 patients (age range, 6-82) with synovial sarcoma.

3 tologic subtype and the clinical behavior of synovial sarcoma.

4 vity were prognostic factors for survival in synovial sarcoma.

5 traditional cytotoxic chemotherapy used for synovial sarcoma.

6 d therapeutic relevance of the SRC kinase in synovial sarcoma.

7 represents a promising therapeutic target in synovial sarcoma.

8 ease stabilization in patients with advanced synovial sarcoma.

9 specific therapeutic interventions to treat synovial sarcoma.

10 el suggest additional nonmyoblast origin for synovial sarcoma.

11 osarcoma, and one (10%) of ten patients with synovial sarcoma.

12 ion of the epithelial structures in biphasic synovial sarcoma.

13 molecules in the tight junction, in biphasic synovial sarcoma.

14 ignificant therapeutic modality for treating synovial sarcoma.

15 ene involved in the t(X;18) translocation in synovial sarcoma.

16 expression of ERBB2, IGFBP2, and IGF2 in the synovial sarcomas.

17 e' fusion to SYT, is a consistent feature of synovial sarcomas.

18 t(X;18)(p11;q11) is detectable in almost all synovial sarcomas.

19 BH3-peptidomimetic pharmacotherapy in human synovial sarcomas.

20 rs CSK and PTP1B (PTPN1) was conducted in 30 synovial sarcomas.

21 that PDGFRA may be uniquely significant for synovial sarcomas.

22 ve shown preliminary evidence of activity in synovial sarcomas.

23 We analyzed SYT-SSX fusion transcripts in 45 synovial sarcomas (33 monophasic and 12 biphasic) by the

24 re performed on individual tumor samples; 14 synovial sarcomas, 4 malignant fibrous histiocytomas, an

25 desmoplastic small round cell tumors, 2 of 3 synovial sarcomas, 4 of 4 leiomyosarcomas, 1 of 1 malign

26 pid signaling associates with progression of synovial sarcoma, a deadly soft tissue malignancy initia

27 Synovial sarcoma, a soft tissue sarcoma that develops in

28 ation, t(X;18)(p11.2;q11.2), which occurs in synovial sarcoma, a soft tissue tumor.

29 Synovial sarcomas account for up to 10 percent of soft-t

30 gene product, SYT-SSX, routinely detected in synovial sarcoma, an aggressive human tumor.

31 ically subclassified into monophasic spindle synovial sarcoma and biphasic synovial sarcoma with epit

32 acquisition of epithelial characteristics in synovial sarcoma and highlight the potential role of dif

33 malignant tumors, such as parosteal sarcoma, synovial sarcoma and malignant fibrous histiocytoma.

34 ifferentiation, is aberrantly derepressed in synovial sarcoma and may also explain the association of

35 patients with high-risk, primary, extremity, synovial sarcoma and should be considered in the treatme

36 sion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse mode

37 e expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulati

38 nscripts are a defining diagnostic marker of synovial sarcomas and may also yield important independe

39 nslocation t(X;18)(p11.2;q11.2) is unique to synovial sarcomas and results in an 'in frame' fusion of

40 on embryonal and alveolar rhabdomyosarcoma, synovial sarcoma, and adult soft tissue sarcomas diagnos

41 g fibrosarcoma, leiomyosarcoma, liposarcoma, synovial sarcoma, and neurofibrosarcoma cells.

42 lisation (six with Ewing's sarcoma, one with synovial sarcoma, and one with fibrosarcoma) lasting 4 m

43 ere observed in patients with Ewing sarcoma, synovial sarcoma, and osteosarcoma.

44 Synovial sarcomas are aggressive soft-tissue malignancie

45 Synovial sarcomas are aggressive spindle cell sarcomas c

46 Synovial sarcomas are high grade spindle cell tumors tha

47 PURPOSE OF REVIEW: Synovial sarcomas are regarded as chemosensitive tumors

48 lial malignancies, these sarcomas (excepting synovial sarcoma) are characterized predominantly by cop

49 distinct expression profile for the group of synovial sarcomas as compared to the other soft tissue s

50 that is associated with a high proportion of synovial sarcoma can be a useful diagnostic aid.

51 ssary for maintaining Igf2 expression in the synovial sarcoma cell line, and the increased IGF2 synth

52 man osteoarthritic cartilage as well as by a synovial sarcoma cell line.

53 used to immunoscreen cDNA libraries from two synovial sarcoma cell lines and normal testis, resulting

54 Analysis of synovial sarcoma cell lines showed that either IGF-1R or

55 cell growth and migration across a series of synovial sarcoma cell lines.

56 tified selective cytotoxicity of EA in human synovial sarcoma cells (SW982 cells) and investigated th

57 We show that mouse and human synovial sarcoma cells are sensitive in vitro to ABT-263

58 PDGFRA or inhibiting its kinase activity in synovial sarcoma cells blocked rapamycin-induced phospho

59 xpressing wt p53 compared with CM from human synovial sarcoma cells expressing mutant p53.

60 rved with conditioned medium (CM) from human synovial sarcoma cells expressing wt p53 compared with C

61 mportantly, depletion of SYT-SSX2 in primary synovial sarcoma cells resulted in loss of nuclear beta-

62 We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expr

63 at EA has a potent cytotoxic effect on human synovial sarcoma cells which is mediated by heteromeric

64 Treatment of synovial sarcoma cells with dasatinib led to apoptosis a

65 enhanced sarcomagenesis without compromising synovial sarcoma characteristics.

66 ing therapeutic strategy in the treatment of synovial sarcoma; clinical trials are initiating enrollm

67 otein expression in tissue microarrays of 37 synovial sarcomas demonstrated strong expression of ERBB

68 LOI) for Igf2 in a limited number of primary synovial sarcomas despite demethylation of CpG dinucleot

69 Despite the name, synovial sarcoma does not typically arise from a synovio

70 Moreover, in a large panel of human synovial sarcomas, enhanced PI3'-lipid signaling also co

71 L2 is considered a consistent feature of the synovial sarcoma expression profile.

72 was agreement on the use of chemotherapy for synovial sarcoma, for high-grade tumors, for tumors larg

73 of NCOA3 is essential for SYT-SSX1-mediated synovial sarcoma formation.

74 chromosomal translocation commonly found in synovial sarcomas fuses the SYT gene on chromosome 18 to

75 e that SYT, a partner protein generating the synovial sarcoma fusion protein SYT-SSX, associates with

76 Patients with synovial sarcoma > or = 5 cm in size, microscopic positi

77 nt in the fusion transcript: all 12 biphasic synovial sarcomas had a SYT-SSX1 fusion transcript, and

78 yrosine kinases have been found activated in synovial sarcoma; however, no convincing therapeutic con

79 investigated EZH2 as a therapeutic target in synovial sarcoma in vitro.

80 Previously, we reported modeling synovial sarcomas in mice by conditionally expressing th

81 Synovial sarcoma is a deadly malignancy with limited sen

82 Synovial sarcoma is a high-grade tumor that is associate

83 Synovial sarcoma is a primitive mesenchymal neoplasm cha

84 Synovial sarcoma is a soft tissue cancer associated with

85 Synovial sarcoma is a soft-tissue malignancy characteriz

86 Synovial sarcoma is an aggressive soft tissue sarcoma ge

87 Synovial sarcoma is an aggressive soft tissue tumor char

88 Synovial sarcoma is an aggressive soft tissue tumor char

89 Synovial sarcoma is an aggressive spindle cell sarcoma w

90 Human synovial sarcoma is caused by a chromosome translocation

91 Like many sarcomas, synovial sarcoma is driven by a characteristic oncogenic

92 ilding the epithelial components in biphasic synovial sarcoma is totally unknown.

93 in the unique translocation t(X;18) found in synovial sarcoma, is known to interact with human BRM (h

94 SYT-SSX2, a fusion also frequently found in synovial sarcoma, is necessary for maintaining Igf2 expr

95 Patients with synovial sarcoma less than 5 cm in size has a cancer-spe

96 ls with altered SWI/SNF complex (e.g., lung, synovial sarcoma, leukemia, and rhabdoid tumors).

97 tissue types leads to exclusive formation of synovial sarcoma-like tumors, whereas its widespread exp

98 ne independent prognostic factors of primary synovial sarcoma localized to the extremity.

99 This review also describes how patients with synovial sarcoma might benefit from future therapy direc

100 = 7), 0 rhabdomyosarcoma (n = 2), and three synovial sarcomas (n = 22).

101 sic and monophasic histological subgroups of synovial sarcoma, notably several keratin genes, and ELF

102 The natural history of primary synovial sarcoma of the extremity is related to tumor si

103 Forty-nine percent of patients with synovial sarcoma on the phase II trial of pazopanib had

104 Meta-analysis of human synovial sarcoma patient series identified two tumor-gen

105 Tumor biopsy analyses from a synovial sarcoma patient treated with the mTORC1 inhibit

106 and metastatic sarcoma tissues from a single synovial sarcoma patient were examined for p53-related a

107 Thus, both in the mouse model and in human synovial sarcomas, PI3'-lipid signaling drives CSF1 expr

108 A subset of synovial sarcoma, predominantly cases with the SYT-SSX1

109 onfirm the distinctive expression profile of synovial sarcoma, provide leads for the study of glandul

110 ural- or neuroectodermal-associated genes in synovial sarcomas relative to the comparison sarcoma gro

111 t(X;18)(p11.2;q11.2) translocation found in synovial sarcomas results in the fusion of the SYT gene

112 (miR)-183 in multiple tumor types including synovial sarcoma, rhabdomyosarcoma (RMS), and colon canc

113 miR-183 knockdown in synovial sarcoma, RMS, and colon cancer cell lines revea

114 Synovial sarcomas, round-cell/myxoid liposarcomas, clear

115 A tissue microarray containing 37 synovial sarcoma samples verified to bear the SYT-SSX fu

116 onfirmed EZH2 expression in the 76% of human synovial sarcoma samples.

117 secutive patients with extremity and truncal synovial sarcomas seen between 1966 and 1994.

118 Ongoing work on the SYT-SSX fusion and synovial sarcoma should yield a variety of data of broad

119 Synovial sarcoma (SS) is a rare sarcoma driven by a tran

120 Synovial sarcoma (SS) is an aggressive soft-tissue malig

121 Synovial sarcoma (SS) is an aggressive soft-tissue sarco

122 Synovial sarcoma (SS) occurs in both children and adults

123 resent study investigates this hypothesis on synovial sarcoma (SS), assessing the frequency of expres

124 Synovial sarcoma (SS), clear cell sarcoma (CCS), and des

125 e the underlying mechanism, we studied human synovial sarcoma (SS), in which transformation results f

126 The synovial sarcoma (SS)-associated protein, SYT-SSX2, repr

127 In contrast to other sarcomas, synovial sarcoma SW982 demonstrated remarkable resistanc

128 in the unique translocation t(X;18) found in synovial sarcoma SYT-SSX fusions.

129 rs) with >or=5 cm, deep, primary, extremity, synovial sarcoma that underwent surgical treatment of cu

130 In synovial sarcoma, the SS18-SSX fusion protein represses

131 In alveolar rhabdomyosarcoma and synovial sarcoma, these variant fusions have been found

132 h EphB2 and Glu tubulin in SYT-SSX2-positive synovial sarcoma tissues.

133 ic variations in the intrinsic resistance of synovial sarcomas to rapamycin and suggest therapeutic s

134 Expression profiles of 21 claudins in 17 synovial sarcoma tumor samples, including 9 biphasic tum

135 omas with characteristic translocations (two synovial sarcomas, two alveolar rhabdomyosarcomas, two d

136 vestigated the pattern of gene expression in synovial sarcoma using cDNA microarrays containing 6548

137 ic survival rate for patients with localized synovial sarcoma was 34% at 10 years.

138 phasic spindle synovial sarcoma and biphasic synovial sarcoma with epithelial components.

139 has been the observation that most cases of synovial sarcoma with glandular epithelial differentiati

140 Patients with synovial sarcoma with less than 10 mitoses per 10 high-p

141 Genes of the synovial sarcoma X breakpoint (SSX) family are expressed

142 r types, the cancer/testis Ag encoded by the synovial sarcoma X breakpoint 2 (SSX-2) gene is among th

143 We identified the synovial sarcoma X breakpoint protein (SSX2IP) as a nove

144 ion of a novel centriolar satellite protein, synovial sarcoma X breakpoint-interacting protein 2 (SSX

145 The synovial sarcoma X chromosome breakpoint (SSX) proteins

146 Eventually, synovial sarcoma xenografts were treated with the SRC in